|
May 21
|
Sanofi to Buy Vigil Neuroscience for About $470 Million
|
|
May 21
|
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
|
|
May 21
|
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
|
|
May 21
|
Viz.ai, Sanofi and Regeneron to link for COPD management
|
|
May 20
|
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management
|
|
May 20
|
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
|
|
May 19
|
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine
|
|
Apr 29
|
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
|
|
Apr 29
|
Regeneron's first-quarter results miss on lower Eylea demand
|
|
Apr 29
|
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
|
|
Apr 28
|
Private Equity Firms Target Defense Assets Once Seen as Toxic
|
|
Apr 25
|
Swiss Agree to Tariff Negotiations With Trump Administration
|
|
Apr 24
|
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
|
|
Apr 24
|
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
|
|
Apr 24
|
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
|
|
Apr 24
|
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
|
|
Apr 24
|
Sanofi stays on course amid tariff turmoil
|
|
Apr 24
|
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
|
|
Apr 24
|
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
|
|
Apr 23
|
Why vaccine makers aren't worried about Trump administration cuts
|